Details for Patent: 12,303,573

« Back to Dashboard

Which drugs does patent 12,303,573 protect, and when does it expire?

Patent 12,303,573 protects AMBELVIST and is included in one NDA.

This patent has twenty-four patent family members in seventeen countries.

Summary for Patent: 12,303,573

Title:	Formulation of contrast media and process of preparation thereof
Abstract:	The present disclosure relates to a liquid pharmaceutical formulation comprising a DO3A-derived tetra-chelate of formula (I), in which M is an ion of a paramagnetic metal, preferably a Gd3+ ion, and R1, R2, R3, R4 and R5 are as defined in the claims, in a pharmaceutical acceptable solvent. The present disclosure also relates to a method of preparation of said liquid pharmaceutical formulation and to a method of imaging involving said liquid pharmaceutical formulation.
Inventor(s):	Stephan Holzschuh, Thomas Frenzel, Gregor Jost, Jessica Lohrke, Wolfgang Ebert, Thomas Brumby, Wolfgang Halfbrodt
Assignee:	Bayer AG , Bayer Pharma AG
Application Number:	US18/617,245
Patent Claim Types: see list of patent claims	Use; Formulation;

Drugs Protected by US Patent 12,303,573

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Bayer Healthcare	AMBELVIST	gadoquatrane	SOLUTION;INTRAVENOUS	219627-001	Jun 12, 2026		RX	Yes	Yes			Y
Bayer Healthcare	AMBELVIST	gadoquatrane	SOLUTION;INTRAVENOUS	219627-002	Jun 12, 2026		RX	Yes	Yes			Y
Bayer Healthcare	AMBELVIST	gadoquatrane	SOLUTION;INTRAVENOUS	219627-003	Jun 12, 2026		RX	Yes	Yes			Y

International Family Members for US Patent 12,303,573

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2019382881
Australia	2025226747
Brazil	112021007707